When you meet somebody, do you [say], “This is how long we’re going to try this, and if I don’t get ‘X,’ we’re changing [treatment]?” KHILLAN: After we start and it doesn’t improve, then they ask what we could expect. BRUNNER: I’m often saying, “I’ll gi...
Those who previously received luspatercept in a clinical trial, any treatment for MDS in a clinical trial prior to beginning luspatercept, or prior therapy with luspatercept for β-thalassemia were not included. The study included a total of 33 patients who were naïve to ESAs. The mean ...
Myelodysplastic syndromes (MDS)The cloning of the erythropoietin (EPO) gene, more than two decades ago [1 ], followed by the production of recombinant human erythropoietin (rHuEPO), allowed millions of patients with anemia to benefit from a novel effective treatment. The patient populations that ...
Cytological patterns in the genus have been a particular focus of attention in the taxonomic treatment of the genus; the base chromosome number for the genus is x = 10 (Gould, 1967; Stebbins, 1975; Norrmann et al., 2004). Most African Andropogon species are diploid or tetraploid (2n =...
MDS-065 Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Nave Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in Routine Clinical Practice in the United States (US)doi:10.1016/S2152-2650(23)01163-1Sudipto Mukherjee MD PhD...
67 Response to ESA treatment in patients with MDS: Determination of a predictive score, from a retrospective analysis of 669 patientsdoi:10.1016/S0145-2126(11)70069-8A. Symeonidis and P. Zikos and A. Galanopoulos and I. Kotsianidis and A. Kouraklis and E. Terpos and M. Protopapa ...
Ultimately, the majority of pts with LR-MDS who receive an ESA will experience ESA treatment failure. This real-world (RW) study aims to describe pt characteristics, treatment patterns including ESA use, and outcomes in pts with LR-MDS.Methods:A retrospective, observational, US multisite, ...
Tthese results also suggest that after the CMS NCD, physicians may have delayed initiation of ESAs until patients were using transfusions, and administered shorter episodes of treatment. Thus policy changes, which were not directed at MDS, may have had a negative impact on adherence to ...
Context There is an unmet need for effective treatments that provide durable benefit for patients with anemia due to lower-risk (LR) MDS. Objective To report clinically meaningful responses to luspatercept treatment in TD, ESA-naive patients with LR-MDS (COMMANDS; NCT03682536). Patients Adults ...
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.doi:10.1200/JCO.2024.42.16_suppl.6565...